drugset / Trial / NCT05622240
99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.
Timeline
- Start
- 2022-09-07
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 99mTc-MIRC213 | Unknown | 11.1 mbq/kg | Intravenous |
| Subject | 99mTc-MIRC213 | Unknown | 14.8 mbq/kg | Intravenous |